Aprea Therapeutics, Inc. (APRE)

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.

Aprea Therapeutics, Inc. (APRE) is down 10.4% since the beginning of the year. At $1 per share, APRE is trading 65.6% below its 52-week high of $2. Investors who bought $1,000 worth of APRE shares 5 years ago would now be looking at an investment worth $8.

Aprea Therapeutics, Inc. (APRE) has returned -10.41% so far this year and -57.54% over the past 12 months.

Based on dividend-adjusted daily data since Oct 3, 2019, APRE's average daily return is -0.19%, while the average monthly return is -4.25%.

Historically, 36% of months were positive and 64% were negative. The best month was Dec 2019 with a return of +82.3%, while the worst month was Dec 2020 at -80.5%. The longest winning streak lasted 4 consecutive months, and the longest losing streak was 7 months.

On a daily basis, APRE closed higher 45% of trading days. The best single day was Jan 30, 2026 with a return of +34.9%, while the worst single day was Dec 28, 2020 at -78.1%.

Aprea Therapeutics, Inc. has an annualized alpha of -45.13%, beta of 0.71, and R2 of 0.03 versus S&P 500 Index. Calculated based on daily prices since October 04, 2019.

• This stock participated in 199.58% of S&P 500 Index downside but only -74.17% of its upside - more exposed to losses than it benefited from rallies.
• R2 of 0.03 means this stock moves largely independently of S&P 500 Index - capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.

APRE ranks 13 for risk / return — in the bottom 13% of stocks on our site. This means you're taking on significantly more risk than the returns justify. Consider whether the potential upside is worth the volatility, or explore alternatives with better risk / return profiles.

The table below present risk-adjusted performance metrics for Aprea Therapeutics, Inc. (APRE) and compare them to S&P 500 Index.

The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.

The table below displays the maximum drawdowns of the Aprea Therapeutics, Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the Aprea Therapeutics, Inc. was 99.94%, occurring on Jan 29, 2026. The portfolio has not yet recovered.

The current Aprea Therapeutics, Inc. drawdown is 99.92%.

The chart below shows the rolling one-month volatility.

The chart below illustrates the trends in the financial health of Aprea Therapeutics, Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.

The Valuation section provides an overview of how Aprea Therapeutics, Inc. is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.